RedHill Advances Opaganib for Ebola Outbreak Response
Raleigh, North Carolina, August 31, 2026 RedHill Biopharma Ltd. announced an update on the emergency development of opaganib as...
Vaccines, Blood & Biologics
Eisai and Biogen Advance LEQEMBI Access in Canada
TOKYO and CAMBRIDGE, Mass., August 31, 2026 Eisai and Biogen announced that Canada’s Drug Agency (CDA-AMC) has issued a...
AN2 Therapeutics Highlights Epetraborole Data for PV at SOHO
MENLO PARK, Calif., August 31, 2026 AN2 Therapeutics, Inc. announced that four abstracts featuring clinical and translational data for...
AIM ImmunoTech Wins U.S. Patent for Ampligen Cancer Therapy
OCALA, Fla., August 31, 2026 AIM ImmunoTech Inc. announced that the U.S. Patent and Trademark Office (USPTO) has granted...
BridgeBio Expands U.S. Access to Rare Disease Medicines
PALO ALTO, Calif., August 31, 2026 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on medicines for...
PharmaEssentia Wins FDA Approval for BESREMi in ET
BURLINGTON, Mass., August 31, 2026 PharmaEssentia announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon...
IDEAYA’s IDE849 Advances Toward Phase 3 in Lung Cancer
South San Francisco, California, August 31, 2026 IDEAYA Biosciences, Inc. announced the successful completion of a U.S. Food and...
Alvotech Wins FDA Review Acceptance for AVT80 Biosimilar
Reykjavik, Iceland – August 31, 2026 Alvotech announced that the U.S. FDA has accepted for review its Biologics License...
AskBio Advances Heart Failure Gene Therapy in Phase 2
Durham, North Carolina, August 29, 2026 AskBio Inc. presented baseline characteristics from its Phase 2 GenePHIT clinical trial evaluating...
Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...